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Nocturia as an Unrecognized Symptom of Uncontrolled Hypertension
in Black Men Aged 35 to 49 Years
Ronald G. Victor, MD; Ning Li, PhD; Ciantel A. Blyler, PharmD; O’Neil R. Mason, MD; L. Cindy Chang, MS; Norma Priscilla B. Moy, BA;
Mohammad A. Rashid, MBChB; Jeffrey P. Weiss, MD; Joel Handler, MD Jeffrey W. Brettler, MD; Michael B. Sagisi, BS; Florian Rader, MD,
MSc; Robert M. Elashoff, PhD
Background-—Hypertension is assumed to be asymptomatic. Yet, clinically significant nocturia (≥2 nightly voids) constitutes a
putative symptom of uncontrolled hypertension. Black men with hypertension may be prone to nocturia because of blunted
nocturnal blood pressure (BP) dipping, diuretic drug use for hypertension, and comorbidity that predisposes to nocturia. Here, we
test the hypothesis that nocturia is a common and potentially reversible symptom of uncontrolled hypertension in black men.
Methods and Results-—We determined the strength of association between nocturia (≥2 nightly voids) and high BP (≥135/
85 mm Hg) by conducting in-person health interviews and measuring BP with an automated monitor in a large community-based
sample of black men in their barbershops. Because nocturia is prevalent and steeply age-dependent after age 50 years, we studied
men aged 35 to 49 years. Among 1673 black men (mean age, 434 years [SD]), those with hypertension were 56% more likely
than men with normotension to have nocturia after adjustment for diabetes mellitus and sleep apnea (adjusted odds ratio, 1.56;
95% CI, 1.25–1.94 [P<0.0001]). Nocturia prevalence varied by hypertension status, ranging from 24% in men with normotension to
49% in men whose hypertension was medically treated but uncontrolled. Men with untreated hypertension were 39% more likely
than men with normotension to report nocturia (P=0.02), whereas men whose hypertension was treated and controlled were no
more likely than men with normotension to report nocturia (P=0.69).
Conclusions-—Uncontrolled hypertension was an independent determinant of clinically important nocturia in a large cross-
sectional community-based study of non-Hispanic black men aged 35 to 49 years.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unqiue identifier: NCT 02321618. ( J Am Heart Assoc. 2019;8:
e010794. DOI: 10.1161/JAHA.118.010794.)
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N on-Hispanic black men have the highest hypertension-attributable death rate of any race, ethnic, or sex group
in the United States.1,2 Black men have less physician
interaction than black women and thus lower rates of
hypertension treatment and control.1–3 In the absence of
bothersome symptoms, men in general—but especially
underserved black men—are less likely than women to see
the need for routine medical checkups, where hypertension
typically is diagnosed and managed.3 A long-held tenet is that
the asymptomatic nature of hypertension reduces risk
perception, thus hindering treatment-seeking behavior and
use of prescription blood pressure (BP) medication. But, is
hypertension truly asymptomatic?
Nocturia—awakening at night to void—constitutes a
putative, but understudied, symptom of uncontrolled hyper-
tension.4 High BP induces natriuresis with diuresis (the main
renal defense against surges in BP). This “pressure-natriur-
esis” relationship is reset in hypertension, causing higher
urine output at night than during the day (nocturnal polyuria).4
Nocturia, the most common cause of disturbed sleep,
becomes clinically important when it occurs ≥2 times per
night.5–7 Repeated arousal from sleep further increases BP
and nocturia,8–10 creating a vicious cycle. The resulting sleep
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fragmentation promotes daytime sleepiness, napping,
impaired quality of life, depression, falls, and absenteeism
from work. It is associated with increased risk of the same
cardiovascular disease events as hypertension, suggesting a
common mechanistic link.6
Both nocturia and hypertension are more prevalent in non-
Hispanic black men than in men of other races/ethnici-
ties.11,12 Black men with hypertension may be especially
prone to nocturia for several reasons. These include a high-
sodium/low-potassium diet and blunted nocturnal dipping of
BP, both of which drive nocturnal pressure-natriuresis13–17;
treatment with diuretics that are often recommended as first-
line BP drugs for black patients with hypertension2; and
common comorbid conditions that are known determinants of
nocturia including prostate disease, diabetes mellitus, sleep
apnea, and salt-retaining/edema-forming states including
venous insufficiency, heart failure, and kidney failure.18
Observational studies that enrolled few or no black people
have found nocturia to be more prevalent in men and women
with hypertension than with normotension; however, the
strength of the association—typically based on a self-
reported history of hypertension rather than BP measure-
ment—varied considerably and some studies found no
association.4,11,19–24
Thus, the goal of this study was to test the hypothesis that
nocturia is a common and potentially reversible symptom of
uncontrolled hypertension in black men. To test this hypoth-
esis, we determined the strength of association between
clinically important nocturia—defined as ≥2 nightly voids—
and high BP by conducting in-person health interviews and
measuring BP in a large community-based sample of black
men in their barbershops, a uniquely relaxed and popular
social setting for engaging black men in clinical research and
obtaining accurate out-of-office BP measurements.25 Because
nocturia prevalence rises steeply after age 50 years (as a
result of prostate disease in men, cardiovascular comorbidity,
and an age-dependent reversal of the normal circadian rhythm
in arginine vasopressin secretion),5 we focused our study on
men aged 35 to 49 years in whom clinically important
nocturia should be relatively uncommon. To examine the
influence of BP level and of antihypertensive drug therapy
alone and in combination, we studied the association of
nocturia with hypertension that was medically untreated,
treated but uncontrolled, or treated and controlled.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Study Population
This cross-sectional study was a prespecified substudy of a
recently published cluster-randomized trial of BP reduction in
52 black-owned barbershops in Los Angeles County, California
(Clinicaltrials.gov, NCT02321618).25 Field interviewers
screened the clientele at participating barbershops to recruit
self-identified regular patrons (≥1 haircut every 6 weeks for
≥6 months) who were non-Hispanic black men aged 35 to
79 years with systolic BP ≥140 mm Hg on 2 screening days.
Women and patients undergoing dialysis and chemotherapy
were excluded. Our analyses in this report are derived from the
men who completed the first screening visit, which included:
(1) a brief in-person computer-based health questionnaire that
provided structured response data on nocturia frequency,
known determinants of nocturia, and other relevant baseline
characteristics; and (2) BP measurements. The study was
approved by institutional review boards at Cedars-Sinai
Medical Center, Kaiser-Permanente, and Westat (the survey
research company that conducted the screening and collected
the data reported in this article). For the first screening visit
only, the institutional review boards waived written consent,
which was replaced by informed verbal consent.
Study Measurements
Nocturia and covariates
Self-reported data on nocturia frequency were obtained using
the same question and structured response items used in
NHANES (National Health and Nutrition Examination Survey):
“During the past 30 days, how many times per night did you
most typically get up to urinate from the time you went to bed
at night until the time you got up in the morning: Would you
say: 0, 1, 2, 3, 4, 5, or more?” Self-reported data on potential
covariates (including age, body mass index, diabetes mellitus,
Clinical Perspective
What Is New?
• Uncontrolled hypertension was an independent determinant
of clinically significant nocturia (≥2 voids per night) in a
large cross-sectional cohort of non-Hispanic black men,
which calls into question the asymptomatic nature of
hypertension.
What Are the Clinical Implications?
• If tight control of blood pressure could alleviate a bother-
some symptom such as nocturia, it would prove a powerful
public health message to increase medication adherence.
• A randomized controlled trial is warranted to test whether
pharmacologic reduction of nighttime blood pressure can
reduce or altogether eliminate nocturia in young black men.
DOI: 10.1161/JAHA.118.010794 Journal of the American Heart Association 2
Nocturia and Uncontrolled Hypertension in Black Men Victor et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
enlarged prostate, prostate cancer, sleep apnea, kidney
disease, stroke, heart attack, and heart failure) were obtained
using standard NHANES questions. To assess hypertension
treatment status, men were asked whether they were now
taking prescription BP pills. Men were also asked whether
they were currently taking any of the following prescription
medication: water pills, insulin or pills for diabetes mellitus, or
pills for enlarged prostate.
BP Measurement
All BPs were measured in the barbershops using a validated
oscillometric monitor (AccutorrV, Mindray).26 To automate
measurement, minimize operator dependence, and eliminate
human transcription error, monitor readings were directly
uploaded to a computer that electronically transmitted data to
a secure website. The protocol required 5 sequential readings,
and discarded the first 2 and averaged the last 3 readings.27
Field interviewers were trained in proper measurement
technique (5 minutes of rest, arm at heart level, back
supported, legs not crossed, no urinary urgency, and no
conversation with participants). The correct arm cuff size was
determined for each participant.
Statistical Analysis
In accordance with current urologic standards,6 nocturia was
defined as ≥2 nightly voids, which is clinically important.
Absence of nocturia was defined as 0 or 1 nightly void. To
assess the external validity of our convenience sample, we
compared age-specific prevalence rates of nocturia in our
barbershop patrons with weighted estimates of US population
prevalence for non-Hispanic black men from the NHANES
2013–2014 (the last NHANES to address nocturia). Also, we
compared hypertension prevalence, hypertension treatment,
and hypertension control rates in our study sample with
weighted estimates from NHANES 2013–2016. The statistical
package of SAS procedure SURVEYFREQ was used for
analyzing NHANES data. WTMEC2YR sample weights and
design variables SDMVSTRA and SDMVPSU were applied in
estimating the nocturia and hypertension-related rates, stan-
dard errors, and 95% CIs. Missing data were rare and thus
assumed to occur at random.
To minimize confounding by prostate disease, we focused
our analyses on men younger than 50 years, above which
prostate disease becomes prevalent and the dominant
determinant of nocturia. We examined the prevalence by
decade of self-reported enlarged prostate, current use of
prescription medications of enlarged prostate, prostate
cancer, and the aggregate of these prostate conditions.
Hypertension was defined as systolic BP ≥135 mm Hg or
diastolic BP ≥85 mm Hg (conventional cutoff values for out-
of-office BP)28 or current use of prescription BP medication.
Hypertension treatment rate was calculated as the percent-
age of patients with hypertension currently using prescription
BP medication. Hypertension control rate was calculated as
the percentage of patients with hypertension with systolic BP
<135 mm Hg and diastolic BP <85 mm Hg.
Summary statistics were generated to describe patient
characteristics for the whole cohort and by the nocturia status
(≥2 nightly voids, yes/no). In the analysis for the association
of nocturia with hypertension, men aged 35 to 49 years with
prostate disease, heart attack, heart failure, stroke, or kidney
disease were excluded because the numbers were small
(Table S1). The association of nocturia with hypertension was
evaluated using logistic regression that included hypertension
(yes/no) as the primary predictor and diabetes mellitus and
sleep apnea as covariates. We also classified hypertension
into categories “untreated,” “treated and controlled,” and
“treated but uncontrolled,” and evaluated the association of
nocturia with these categories (normotension as the refer-
ence) using logistic regression while adjusting for diabetes
mellitus and sleep apnea. We further evaluated the effect of
diuretic use on the odds of nocturia by classifying “treatment
and controlled” and “treated but uncontrolled” into subgroups
with and without diuretic use. An additional logistic regression
analysis was performed to determine whether nocturia is a
predictor of uncontrolled hypertension in treated patients. In
this analysis, we adjusted for age, diabetes mellitus, and sleep
apnea.
Analyses were conducted using SAS (version 9.4 for
Windows, SAS Institute). All tests were 2-sided. P<0.05 was
considered statistically significant.
Results
Sample Selection and Validation
As expected, nocturia prevalence increased with age. At each
decade of life, the percentage of black male barbershop
patrons reporting ≥2 nightly voids corresponded closely with
weighted US population prevalence estimates from NHANES
and were well within the 95% CIs (Figure 1). Among our
participants, the prevalence of reported aggregate prostate
disease, and its individual components, increased exponen-
tially after age 49 years (Figure 2). Thus, to study the
association of nocturia with hypertension, we focused our
analyses on younger men aged 35 to 49 years.
Of 4027 black male barbershop patrons aged 35 to
79 years who completed all data collection for the initial
screening visit, we excluded from analysis 2279 patrons aged
50 years and older (Figure S1). We excluded an additional 75
patrons with potentially confounding comorbidities because
the number of patrons with each comorbid condition was too
DOI: 10.1161/JAHA.118.010794 Journal of the American Heart Association 3
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small to include in logistic regression. Thus, the primary
analysis included 1673 men aged 35 to 49 years. Among
these, hypertension prevalence (43.9%) and rates of
hypertension treatment and control (15%) corresponded
closely with NHANES data and were well within the 95% CIs
(Table S2).
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Figure 1. Age-specific prevalence of nocturia (≥2 nightly voids) in non-Hispanic black men aged 35 to
79 years: Los Angeles Barbershop Sample (blue bars) vs NHANES (National Health and Nutrition
Examination Survey) data weighted to the US population (yellow bars). Weighted data are from the 2013–
2014 survey, which was the most recent survey that asked about nocturia. Error bars represent 95% CIs.
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Figure 2. Age-specific prevalence of prostate disease in the Los Angeles Barbershop Sample. Data are by
participant self-report. Error bars represent standard error.
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Hypertension is an Independent Determinant of
Nocturia in Black Men Aged 35 to 49 Years
Overall, 29% of the final sample reported clinically significant
nocturia. Compared with men reporting 0 or 1 nightly void,
those with nocturia (≥2 nightly voids) had similar mean age
and body mass index but, as expected, reported a higher
prevalence of both diabetes mellitus and sleep apnea
(Table 1). Hypertension was present in 53% of men with
nocturia compared with 40% of men without nocturia. Men
with hypertension were 56% more likely than men with
normotension to have nocturia after adjustment for diabetes
mellitus and sleep apnea (adjusted odds ratio [OR], 1.56; 95%
CI, 1.25–1.94 [P<0.0001]) (Table 2).
Treated But Uncontrolled Hypertension is a
Particularly Strong Determinant of Nocturia
Nocturia varied by hypertension status, ranging from 24% of
men with normotension to 49% of men whose hypertension
was treated but uncontrolled (Table 3).
Men with treated but uncontrolled hypertension were 2.63
times more likely than men with normotension to report ≥2
nightly voids (adjusted OR, 2.63; 95% CI, 1.85–3.74
[P<0.0001]) (Table 3 and Figure 3). Men with untreated
hypertension were 39% more likely than men with normoten-
sion to report ≥2 nightly voids (P=0.0097), whereas men
whose hypertension was treated and controlled were no more
likely than men with normotension to report ≥2 nightly voids
(Table 3 and Figure 3). The adjusted OR for nocturia was
considerably higher for patients with hypertension that was
treated but uncontrolled than for patients with untreated
hypertension (P<0.0008, Figure 3).
Based on the above findings, additional logistic regressions
were performed. The first was aimed at determining the effect
of diuretic use on nocturia. Among patients with treated and
controlled hypertension, diuretic use increased the odds of
nocturia after adjustment for both diabetes mellitus and sleep
apnea (P<0.03, Table S3). However, there was no statistically
significant difference in the odds among patients with treated
uncontrolled hypertension (P=0.39). The second analysis was
performed to determine whether nocturia is a predictor (ie, a
symptom) of uncontrolled hypertension in treated patients.
Among patients with treated hypertension, men with nocturia
were 2.47 times more likely to have elevated BP after
adjustment for age, diabetes mellitus, and sleep apnea
(adjusted OR, 2.47; 95% CI, 1.46–4.17 [P=0.0007]) (Table S4).
Discussion
In a large community-based sample of non-Hispanic black
male barbershop patrons aged 35 to 49 years without known
prostate disease or prior cardiovascular events or kidney
disease, we found that clinically important nocturia was
common and positively associated with both high BP per se
and BP drug therapy. By far, the strongest association was in
men who were using prescription BP medication but still had
elevated BP. These men were 2.63 times more likely to have
nocturia than men with normotension. Among patients with
treated hypertension, those with nocturia were 2.47 times
more likely to have uncontrolled high BP. Thus, these data
implicate nocturia as a common symptom of uncontrolled
hypertension—especially unsuccessfully treated hypertension
—among relatively young middle-aged black men.
The 29% overall prevalence rate of ≥2 nightly voids in our
study (as in NHANES) is 2 to 3 times higher than what has
been reported for men of this age group in white US and
European population studies, as well as in Asian men.18,22–32
Our data indicate that a major factor in this exceptionally high
Table 1. Characteristics of Barbershop Patrons Aged 35 to
49 Years
0 or 1
Nightly
Void
≥2 Nightly
Voids
All
Patients
P Value
(0 or 1 vs ≥2
Nightly Voids)
No. (%) 1196 (71) 477 (29) 1673 (100)
Age, mean
SD, y*
434 434 434 0.1704
Body mass
index, kg/m2*
306 317 306 0.0001
Diabetes
mellitus*
68 (6) 55 (12) 123 (7) <0.0001
Sleep apnea* 85 (7) 56 (12) 141 (8) 0.0021
Hypertension 481 (40) 254 (53) 735 (44) <0.0001
Values are expressed as number (percentage) or meanSD.
*Values are by participant self-report, except for hypertension, which was determined by
both blood pressure measurement and self-report of current use of prescription blood
pressure medication.
Table 2. Logistic Regression for Nocturia (≥2 Nightly Voids
vs 0 or 1 Nightly Void)
Unadjusted OR
(95% CI) P Value
Adjusted OR
(95% CI)
P
Value
Hypertension 1.69
(1.37–2.10)
<0.0001 1.56
(1.25–1.94)
<0.0001
Diabetes
mellitus
2.16
(1.49–3.14)
<0.0001 1.83
(1.25–2.68)
0.0018
Sleep apnea 1.74
(1.22–2.48)
0.0023 1.48
(1.03–2.13)
0.0352
OR indicates odds ratio.
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rate of nocturia in young black men is a high prevalence of
hypertension (44%) combined with a low rate of hypertension
control—only 15%. Men with untreated hypertension were
39% more likely to have nocturia than men with normoten-
sion, indicating that high BP per say constitutes an indepen-
dent determinant of nocturia. On one hand, the adjusted OR
of 1.39 seems modest given that mean systolic BP was
24 mm Hg higher in patients with untreated hypertension
than in men with normotension. On the other hand, the
strength of association may be underestimated, being based
on daytime BP rather than nighttime BP, which is the putative
proximate stimulus to nocturnal pressure-natriuresis.
The seminal finding of this study is the striking association
between high BP and nocturia in men who were under medical
treatment for hypertension. That the adjusted OR for nocturia
was almost 2 times higher for high BP in presence than
absence of drug treatment suggests several plausible expla-
nations. First, men with treated but uncontrolled hypertension
likely had much higher BP before treatment. Also, they likely
had longer-standing hypertension, which is associated with
dysregulation of renal sodium transporters and blunting or
reversal of the normal nocturnal dip in BP.13,33 Second, mean
systolic BP was 4 mm Hg higher and diastolic BP 5 mm Hg in
men with treated uncontrolled hypertension than those with
untreated hypertension. The relationship between high BP and
nocturia could be exponential rather than linear. Third,
nocturia has been implicated as a potential side effect of
diuretics and calcium channel blockers—2 classes of BP
drugs that are recommended as first-line treatment for
hypertension in black patients2,28; however, the existing
evidence for this assertion is inconclusive.21,34–38 While this
study assessed diuretic usage, we did not collect drug-specific
data (ie, diuretic type and time of administration). Although
diuretic use did increase the odds for significant nocturia
among patients with hypertension with controlled hyperten-
sion, the magnitude of the increased odds was smaller than
the odds associated with uncontrolled hypertension, both with
and without diuretic use. This leads us to hypothesize that
tighter control of BP may help overcome any propensity of BP
drugs to cause nocturia.
Study Limitations
Our study has several limitations. The data are cross-
sectional and correlational and thus do not prove causal
1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 1 6 0
0
1
2
3
4
M ea n S B P (m m H g )
A
d
ju
st
ed
O
R
an
d
9
5
%
C
If
o
r
N
o
ct
u
r i
a
2.63
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p < 0.0001
1.39 
(1.08 – 1.79)
p = 0.0097
1.10 
(0.69 – 1.73) 
p=0.6969
NT (reference group)
Untreated HTN
HTN Treated, Uncontrolled
HTN Treated, Controlled
p = 0.0008*
Figure 3. Adjusted odds ratios (ORs) and 95% CIs for nocturia
plotted against group mean values for systolic blood pressure
(SBP). *A statistically significant difference exists between the
adjusted ORs for men with treated but uncontrolled hypertension
(HTN) vs those with untreated hypertension (P=0.0008).
Table 3. Prevalence and Odds of Nocturia (≥2 Nightly Voids) by Hypertension Status
SBP, meanSD,
mm Hg
DBP, meanSD,
mm Hg
Nocturia
Percentage OR (95% CI)* P Value
Normotension† 1209 717 24 1.00 
Hypertension     
Treated, uncontrolled 14814 9111 49 2.63 (1.85–3.74) <0.0001
Untreated 14412 8710 31 1.39 (1.08–1.79) 0.0097
Treated, controlled 1238 747 29 1.10 (0.69–1.73) 0.6969
DBP indicates diastolic blood pressure; OR, odds ratio; SBP, systolic blood pressure.
*Adjusted for diabetes mellitus and sleep apnea.
†Reference group.
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attribution. However, compared with prior observational
studies that tested for an association between hypertension
and nocturia, ours had the largest sample of black men and
was the only one to measure BP.4,11,19–23 We may have
overestimated the strength of association of nocturia with
high BP relative to its association with diabetes mellitus and
sleep apnea, which were based on self-report and thus their
prevalence was likely underestimated. Undiagnosed diabetes
mellitus, undiagnosed sleep apnea, or undiagnosed prostate
disease may have contributed in part to the unexplained
24% prevalence rate of nocturia in our participants with
normotension. Nondipping of nocturnal BP (ie, isolated
nocturnal hypertension), which is common in black
people14,39–43 but not assessed in our study, also may have
contributed to nocturia in men who have normotension by
in-barbershop (daytime) BP. The BP was measured at a
single point in time, which can overestimate BP levels and
underestimate hypertension control rates. However, hyper-
tension prevalence and control rates, as well as our age-
specific prevalence rates for self-reported nocturia in our
convenience sample, were comparable to nationally repre-
sentative NHANES data. While we collected general infor-
mation on BP medication and diuretic use, we did not
collect drug-specific data. Finally, our health questionnaire
did not ask about insomnia, shift work, and alcohol use—all
potential confounders that were not taken into account in
the analysis. Future randomized controlled trials should
exclude men with these conditions.
The data herein confirm and extend prior studies implicat-
ing high BP as a cause for nocturia. Hypertension by self-
report was an independent determinant of ≥2 nightly voids in
men in both NHANES11 and the Korean Community Health
Survey.29 In an in-patient study of older Danish men with
intermittent nocturia, nocturnal BP (by ambulatory monitoring)
averaged 12 mm Hg higher on nights when men experienced
nocturia than on nights without nocturia.30 In older Japanese
men, nocturnal polyuria was positively related to daytime BP31
and high nocturnal systolic BP and impaired nocturnal BP
dipping by ambulatory BP monitoring.32,44
Our findings call into question the assumption that
uncomplicated hypertension is asymptomatic and thus have
potential practical implications for both patients and provi-
ders. In young middle-aged black men who are under medical
treatment for hypertension, nocturia may be a common
symptom of uncontrolled hypertension that merits further
medical attention. Based on the strength of the BP-nocturia
associations reported here, we believe that a randomized
controlled treatment trial is warranted to test whether
pharmacologic reduction of nocturnal high BP can alleviate
nocturia in young black men. If tight control of nocturnal as
well as daytime hypertension were proven to eliminate
bothersome nocturia and thus improve sleep in such patients,
this would generate a powerful public health message to
enhance BP medication compliance.
Conclusions
Uncontrolled hypertension—especially in medically treated
patients—was an independent determinant of clinically
important nocturia in a large cross-sectional community-
based study of non-Hispanic black men 35 to 49 years. A
randomized treatment trial to demonstrate the effect of
hypertension treatment and control on nocturia is warranted.
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SUPPLEMENTAL MATERIAL 
  
Table S1. Study Cohort Characteristics (N=4027, Ages 35-79)*. 
Nocturia Frequency Ages 35-49 
Cohort A 
Ages 35-49 
Cohort B 
Ages 50-79 All patients 
N (%) 1673 (42) 1748 (43) 2279 (57) 4027 
Known Determinants 
   
 
      Age (years), Mean ± SD 43 ± 4 43 ± 4 60 ± 7 53 ± 11 
      Enlarged Prostate, N (%) 0 19 (1) 289 (13) 308 (8) 
      Diabetes, N (%) 123 (7) 139 (8) 498 (22) 637 (16) 
      Sleep Apnea, N (%) 141 (8) 157 (9) 292 (13) 449 (11) 
Other Comorbidities     
      Body Mass Index, Mean ± SD 30 ± 6 30 ± 6 30 ± 6 30 ± 6 
      Prostate Cancer, N (%) 0 7 (0) 126 (6) 133 (3) 
      Heart Attack, N (%) 0 17 (1) 80 (4) 97 (2) 
      Heart Failure, N (%) 0 8 (0) 62 (3) 70 (2) 
      High Cholesterol, N (%) 274 (16) 305 (17) 771 (34) 1076 (27) 
      Stroke, N (%) 0 18 (1) 77 (3) 95 (2) 
      Kidney Disease, N (%) 0 17 (1) 54 (2) 71 (2) 
 
*All p values are less than 0.05 when comparing cohort A (and cohort B) ages 35-49 with the 
ages 50-79 group. 
†For ages 35-49Y, there are two cohorts: cohort A excludes patients with the co-morbidities 
prostate disease, heart attack, heart failure, kidney disease, and stroke; cohort B includes 
patients with these conditions. 
 
 
 
 
 
 
Table S2. Hypertension Status of Non-Hispanic Black Men Ages 35-49 Years:  
Los Angeles Barbershop Sample vs. NHANES (2013-2016)*. 
 
 
Los Angeles 
Barbershop 
Sample 
NHANES*  
(USA) 
  N  Weighted N  
Normotensive  938  1,702,425 
 
N  
(%) 
Weighted N 
(%) 
95% CI 
Hypertensive  735 1,328,768 - 
      Untreated†  459  
(62) 
766,088  
(58) 
 
(46 – 69) 
      Treated, Uncontrolled†  168  
(23) 
352,451  
(26) 
 
(18 – 35) 
      Treated, Controlled†  108  
(15) 
210,228  
(16) 
 
(8 – 23) 
 
CI, confidence interval 
 
*NHANES denotes National Health and Nutrition Examination Survey. NHANES values were 
weighted to represent the total United States population. Data presented are combined from the 
2013-2014 and 2015-2016 surveys.  
 
† Data are represented as sample size (percentage of the hypertensive sample) for each 
hypertension subgroup.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3. Logistic Regression for Nocturia (≥ 2 nightly voids) With or Without Diuretics.  
(N = 1673). 
 
 
OR 95% CI p-value 
Diabetes 1.71 (1.14, 2.55) 0.0088 
Sleep Apnea 1.46 (1.00, 2.11) 0.0475 
NT reference   
Untreated HTV 1.39 (1.08, 1.79) 0.0097 
Treated HTV Controlled* 
(not on water pills) 
 
0.74 (0.40, 1.36) 0.3273 
Treated HTV Uncontrolled† 
(not on water pills) 
 
2.38 (1.57, 3.61) <.0001 
Treated HTV Controlled* 
(on water pills) 
 
1.95 (1.00, 3.80) 0.0495 
Treated HTV Uncontrolled† 
(on water pills) 
 
3.15 (1.82, 5.45) <.0001 
 
*p-value for the comparison of “Treated HTV Controlled on water pills” vs. “Treated HTV 
Controlled not on water pills” is 0.0279. 
 
†p-value for the comparison of “Treated HTV Uncontrolled on water pills” vs. “Treated HTV 
Uncontrolled not on water pills” is 0.39. 
 
 
 
 
 
 
 
 
Table S4. Logistic Regression for Nocturia (≥ 2 nightly voids) as a Determinant of Blood 
Pressure ≥ 135/85 mm Hg among Treated Hypertensives. 
 
 
aOR 95% CI p-value 
Nocturia  2.47  (1.46 – 4.17) 0.0007 
Age 1.04 (0.98 – 1.10) 0.2174 
Diabetes 1.13 (0.62 – 2.03) 0.6936 
Sleep Apnea 0.72  (0.38 – 1.37) 0.3201 
 
aOR, adjusted odds ratio; CI, confidence interval 
  
Figure S1. Sample Selection. 
 
 
 
